26.8 C
New York
Thursday, July 3, 2025

Tag: wheelchair

newssourcecompanyFORcontentinformation1marketbusiness

101 Mobility of Central New Jersey Celebrates Grand Opening with Mayor Wahler and Chamber of Commerce

PISCATAWAY, N.J., July 2, 2025 /PRNewswire/ -- 101 Mobility of Central New Jersey officially marked the opening of its new location with a vibrant...

Pioneering Global Presence, Empowering the World – Zuowei Technology Shining at WHX Miami Medical Expo

SHENZHEN, China, July 1, 2025 /PRNewswire/ -- From June 11 to 13, the 2025 WHX Miami Medical Expo (formerly known as FIME), the annual grand event...

From Wheelchair to Workhorse: Rapper with MS Builds a Brand, Drops Memoir That’s Moving More Than Music

Robert "B-Cide" Cardillo II's book "Myelin My Shoes" is now available, blending memoir, music, and merch into one powerful package. UTICA, N.Y., June 23, 2025...

123Invent Inventor Develops Stable Leg Platform for Use with Wheelchairs (CSK-1033)

PITTSBURGH, June 20, 2025 /PRNewswire/ -- "After my son's operation, he needed a better way to rest his leg when using the wheelchair," said...

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

2025 Heyball Parasport World Championship Opens in Brisbane, Championing Olympic Inclusion

BRISBANE, Australia, June 13, 2025 (GLOBE NEWSWIRE) -- The 2025 Heyball Parasport World Championship commenced at Brisbane Cricket Groud (the Gabba) with a grand opening ceremony, featuring its anthem "Nothing is Gonna Hold You Back." Jointly presented by JOY & Liber Win, the event gathers 64 outstanding athletes with disabilities from 17 countries and regions, declaring their passion for barrier-free sport on the Heyball table.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsWheelchair

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers